ArticleHealth science reports2026
Clinical Discovery and Molecular Analysis of Two Novel MSH2 Gene Mutations (p.Ala771Gly and p.Val797Gly) in Saudi Colorectal Cancer Patients: Potential Implications for Tumorigenesis.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Colorectal cancer (CRC) is a serious global health problem, ranking first in men and third in women among all cancers worldwide. The genetic basis for CRC remains unclear in most cases; therefore, the present study aimed to investigate the molecular genetic basis of CRC and correlate it with disease outcomes. Methods: Tumor tissues were obtained from 84 Saudi CRC patients, and their disease data and tumor characteristics were recorded. The MutS homolog 2 ( Results: A total of 17 variants in four CRC types were identified in 14 patients of whom two were novel missense variations, c.2312 C > G (p.Ala771Gly) and c.2390 T > G (p. Val797Gly). The p.Ala771Gly variant was detected in five individuals (5.95% allelic frequency), while the p.Val797Gly variant was found in three patients (3.57% allelic frequency). Further analysis using the Have (y)Our Protein Explained (HOPE) tool predicted that these variants may deleteriously affect MSH2 protein-DNA and ATP binding, resulting in functional damage to MSH2, which impairs its functions and protein-binding affinities. Conclusion: This study provides new insights into the genetic basis of CRC and highlights the importance of molecular analysis for detecting novel variants. These novel mutations can be therapeutic targets for novel drugs in precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.